Assembly Biosciences (NASDAQ:ASMB) Shares Gap Up – Here’s What Happened

Assembly Biosciences, Inc. (NASDAQ:ASMB) shares gapped up before the market opened on Wednesday . The stock had previously closed at $30.01, but opened at $32.88. Assembly Biosciences shares last traded at $32.8750, with a volume of 4,670 shares changing hands.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on ASMB shares. Wall Street Zen lowered Assembly Biosciences from a “strong-buy” rating to a “hold” rating in a research report on Saturday, May 16th. HC Wainwright reissued a “buy” rating and set a $50.00 target price on shares of Assembly Biosciences in a research report on Tuesday. Guggenheim restated a “buy” rating and set a $43.00 price target on shares of Assembly Biosciences in a research note on Thursday, May 28th. Mizuho set a $45.00 price target on shares of Assembly Biosciences and gave the stock an “outperform” rating in a report on Monday, June 15th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Assembly Biosciences in a report on Friday, July 17th. Five equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $44.00.

Assembly Biosciences Stock Up 1.8%

The business’s 50-day moving average price is $26.43 and its 200 day moving average price is $27.44. The company has a market capitalization of $520.08 million, a P/E ratio of 32.24 and a beta of 1.10.

Assembly Biosciences (NASDAQ:ASMB) last posted its earnings results on Thursday, August 13th. The biopharmaceutical company reported ($0.20) EPS for the quarter, topping the consensus estimate of ($0.72) by $0.52. The business had revenue of $13.37 million during the quarter, compared to analysts’ expectations of $8.60 million. Assembly Biosciences had a negative return on equity of 0.02% and a negative net margin of 0.06%. Analysts anticipate that Assembly Biosciences, Inc. will post 1.9 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. Stempoint Capital LP grew its position in Assembly Biosciences by 18.3% during the first quarter. Stempoint Capital LP now owns 185,435 shares of the biopharmaceutical company’s stock valued at $5,146,000 after acquiring an additional 28,707 shares during the last quarter. Eversept Partners LP bought a new stake in shares of Assembly Biosciences in the 4th quarter worth approximately $5,431,000. 683 Capital Management LLC purchased a new stake in shares of Assembly Biosciences in the 4th quarter valued at $948,000. Bank of America Corp DE grew its holdings in shares of Assembly Biosciences by 113.3% during the 1st quarter. Bank of America Corp DE now owns 10,902 shares of the biopharmaceutical company’s stock valued at $303,000 after purchasing an additional 5,792 shares during the last quarter. Finally, Renaissance Technologies LLC grew its holdings in shares of Assembly Biosciences by 69.4% during the 1st quarter. Renaissance Technologies LLC now owns 15,651 shares of the biopharmaceutical company’s stock valued at $434,000 after purchasing an additional 6,411 shares during the last quarter. Institutional investors own 19.92% of the company’s stock.

About Assembly Biosciences

Assembly Biosciences, Inc (NASDAQ: ASMB) is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of novel therapies for hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. The company’s core expertise lies in small-molecule modulation of viral proteins and host-targeted pathways to achieve sustained viral suppression and potential functional cure. Assembly’s research model integrates medicinal chemistry, structural biology and translational virology to advance its pipeline from early discovery through clinical development.

The company’s lead programs include core protein allosteric modulators (CpAMs) designed to disrupt the HBV lifecycle by interfering with capsid assembly and viral DNA replication, as well as prenylation inhibitors targeting the HDV lifecycle.